LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

Kodu・Aktsiate loetelu・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Avatud

SektorTervishoid

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-0.05% downside

Uudiste sentiment

By Acuity

29%

71%

74 / 374 Pingereas Healthcare

Mirati Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

26. nov 2025, 17:44 UTC

Tulu

Suurimad hinnamuutused turgudel

Deere Warns of Tough Year Ahead as Earnings, Sales Fall -- Update

27. nov 2025, 00:00 UTC

Market Talk

Rio Tinto's Coming Investor Briefing Seen Focused on Costs, Lithium, Asset Sales -- Market Talk

26. nov 2025, 23:47 UTC

Market Talk

Nikkei May Rise as Fears About Potential AI Bubble Ease -- Market Talk

26. nov 2025, 23:28 UTC

Market Talk

Mortgage Refinancing in New Zealand Will Spur Recovery -- Market Talk

26. nov 2025, 23:21 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

26. nov 2025, 23:21 UTC

Market Talk

RBNZ Rate Cuts Finally Getting Traction With Consumers -- Market Talk

26. nov 2025, 23:02 UTC

Market Talk

Steelmaking Coal Price Signal Knocked by China Import Shift -- Market Talk

26. nov 2025, 21:38 UTC

Tulu

These Stocks Moved the Most Today: Alphabet, Nvidia, AMD, Apple, Dell, Robinhood, Deere, HP Inc., Urban Outfitters, and More -- Barrons.com

26. nov 2025, 21:25 UTC

Tulu

Li Auto Posts Surprise Loss, Stock Rises. What's Next for Its Diving EV Sales. -- Barrons.com

26. nov 2025, 21:17 UTC

Omandamised, ülevõtmised, äriostud

Commercial Metals Co Announces Closing of $2B Senior Notes Offering

26. nov 2025, 21:16 UTC

Tulu

Deere Beat Earnings Estimates. Why the Stock Is Falling. -- Barrons.com

26. nov 2025, 21:09 UTC

Tulu

Roblox Isn't Playing Games. Why the Stock Could -2-

26. nov 2025, 21:09 UTC

Tulu

Roblox Isn't Playing Games. Why the Stock Could Jump 50%. -- Barrons.com

26. nov 2025, 20:27 UTC

Omandamised, ülevõtmised, äriostud

Charter Communications Stock Is a Disaster. The Answer Could Be a 10% Dividend. -- Barrons.com

26. nov 2025, 20:25 UTC

Omandamised, ülevõtmised, äriostud

Charter Communications Stock Is a Disaster. The Answer Could Be a 10% Dividend. -- Barrons.com

26. nov 2025, 20:15 UTC

Tulu

These Stocks Are Moving the Most Today: Alphabet, Nvidia, AMD, Apple, Dell, Robinhood, Deere, HP Inc., Urban Outfitters, and More -- Barrons.com

26. nov 2025, 20:08 UTC

Market Talk

Oil Futures Settle Higher in Choppy Trade -- Market Talk

26. nov 2025, 20:06 UTC

Market Talk

U.S. Natural Gas Settles Higher Ahead of Holiday -- Market Talk

26. nov 2025, 19:30 UTC

Tulu

These Stocks Are Moving the Most Today: Alphabet, Nvidia, AMD, Apple, Dell, Robinhood, Deere, HP Inc., Urban Outfitters, and More -- Barrons.com

26. nov 2025, 19:21 UTC

Omandamised, ülevõtmised, äriostud

Teck Resources: ISS and Glass Lewis Recommend Teck Hldrs Vote for Anglo American Deal

26. nov 2025, 18:43 UTC

Market Talk

U.S. Natural Gas Storage Down for Second Straight Week -- Market Talk

26. nov 2025, 18:41 UTC

Market Talk

U.S. Oil Rig Count Falls By 12 to 407 -- Market Talk

26. nov 2025, 18:19 UTC

Tulu

Workday Beat Earnings Estimates. The Stock Is Down 10% Anyway. -- Barrons.com

26. nov 2025, 17:51 UTC

Tulu

Deere Forecasts Higher Tariff Costs, Less Profit in 2026 -- WSJ

26. nov 2025, 17:50 UTC

Tulu

These Stocks Are Moving the Most Today: Alphabet, Nvidia, AMD, Apple, Dell, Robinhood, Deere, HP Inc., Urban Outfitters, and More -- Barrons.com

26. nov 2025, 17:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Energy & Utilities Roundup: Market Talk

26. nov 2025, 17:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

26. nov 2025, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

26. nov 2025, 17:16 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Blue Owl Is Having a Rough Year. Its Co-CEO Says -2-

26. nov 2025, 17:16 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Blue Owl Is Having a Rough Year. Its Co-CEO Says Investors' Fears Are 'Ungrounded.' -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Mirati Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-0.05% langus

12 kuu keskmine prognoos

Keskmine 58.67 USD -0.05%

Kõrge 59 USD

Madal 58 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Mirati Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Mirati Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

74 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.